Radiographic and computed tomographic studies of calcium hydroxylapatite for treatment of HIV-associated facial lipoatrophy and correction of nasolabial folds.
OBJECTIVE
This study sought to assess the radiographic appearance produced by calcium hydroxylapatite soft tissue filler (CaHA; Radiesse, BioForm Medical Inc.) following augmentation to correct the nasolabial folds or facial wasting associated with human immunodeficiency virus lipoatrophy.


METHODS
A total of 58 patients, with either lipoatrophy or pronounced nasolabial folds, were treated with CaHA. Radiographic (X-ray) and computed tomographic (CT) imaging studies were conducted pre- and posttreatment in most patients; the images were sent to an independent laboratory to be analyzed by two evaluators who were board-certified radiologists and blinded to study purpose, product, and patient condition.


RESULTS
While results for X-ray evaluation showed inconsistencies in visualization of CaHA, CT scans showed consistent visualization in nearly all cases in patients who were imaged immediately after treatment. In addition, the results indicated no obscuration of underlying structures by CaHA and no evidence of CaHA migration.


CONCLUSIONS
Earlier clinical trials established CaHA as a safe and effective soft tissue filler. This CaHA study shows no overt radiographic safety concerns. CaHA is unlikely to be confused with conventional abnormal and adverse radiographic findings. The product is not always visible on X-ray. Although usually visible on CT scans, its appearance is distinct from surrounding bony structures and does not interfere with normal analysis. In addition, the product does not obscure underlying structures on CT scans.
Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada. alastair@carruthers.net
Alastair
A
Carruthers
Marc
M
Liebeskind
Jean
J
Carruthers
Bruce B
BB
Forster
D000328:Adult; D000369:Aged, 80 and over; D000886:Anthropometry; D001672:Biocompatible Materials / Q000008:administration & dosage* / Q000009:adverse effects; D003357:Cosmetic Techniques / Q000009:adverse effects; D017886:Durapatite / Q000008:administration & dosage* / Q000009:adverse effects; D005145:Face / Q000000981:diagnostic imaging*; D005260:Female; D005500:Follow-Up Studies; D039682:HIV-Associated Lipodystrophy Syndrome / Q000000981:diagnostic imaging / Q000628:therapy*; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D016037:Single-Blind Method; D015595:Skin Aging; D014057:Tomography, X-Ray Computed; D014965:X-Rays
D001672:Biocompatible Materials; D017886:Durapatite